This whale alert can help traders discover the next big trading opportunities. Whales are entities w

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Prov

The health care sector's most oversold stocks are a buying opportunity due to undervalued compan

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consen

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prev

Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced m

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stag

Vaxcyte's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prev

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 a

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 a

Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% dur

Citigroup Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 27.1% in the third qua

BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price targe

Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.80) per share which missed the analyst consen

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FD

China Universal Asset Management Co. Ltd. lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ:

Vaxcyte (NASDAQ: PCVX) executives used a presentation at an annual biotech summit to highlight progr

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that the f

Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomi

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage

Federated Hermes Inc. raised its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 6,856.3% in the undefin

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage

From a sector perspective, strength within Industrials and Information Technology offset relative we

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it h

Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studie

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Ad

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price t

Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study De

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.56) per share which missed the analyst consen

Thermo Fisher sells four-part dollar bonds as U.S. investment-grade issuance tops $200 billion, with

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced a new agre

Goldman Sachs analyst Asad Haider initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Neutral rat

Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV

Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity v